Diabetic nephropathy (DN) is characterized by metabolic disorder and inflammation. However, the regulatory effects that long noncoding RNAs (lncRNAs) have on the pathogenesis of DN and on the efficacy of rosiglitazone treatment has yet to be clearly defined. Herein, we performed unbiased RNA sequencing to characterize the transcriptomic profiles in db/db diabetic mouse model with or without rosiglitazone treatment that served to improve the phenotypes of DN. Differential expression analysis revealed that those genes that had their expression restored following treatment with rosiglitazone are likely involved in protection against DN. Our data elucidate the novel renoprotective molecular mechanism of PPAR agonists and propose lncRNA targets for diabetic nephropathy treatment. SOURCE: Liwen Zhang Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Pluto Bioinformatics

GSE139987: Altered expression of long non-coding and messenger RNAs in diabetic nephropathy following treatment with rosiglitazone